These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 23924585)

  • 1. Sustained virological response and baseline predictors in HIV-HCV coinfected patients retreated with pegylated interferon and ribavirin after failing a previous interferon-based therapy: systematic review and meta-analysis.
    Basso M; Parisi SG; Mengoli C; Gentilini V; Menegotto N; Monticelli J; Nicolè S; Cruciani M; Palù G
    HIV Clin Trials; 2013; 14(4):127-39. PubMed ID: 23924585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
    Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM;
    J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients.
    Carosi G; Bruno R; Cariti G; Nasta P; Gulminetti R; Galli M; Angarano G; Verucchi G; Pontali E; Capetti A; Raise E; Ravasio V; Maida I; Iannacone C; Caputo A; Puoti M
    Antivir Ther; 2014; 19(8):735-45. PubMed ID: 24583976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.
    Peribañez-Gonzalez M; da Silva MH; Vilar FC; Seixas-Santos Nastri AC; Ferreira PA; Focaccia R; Mendes Correa MC
    Ann Hepatol; 2013; 12(2):228-35. PubMed ID: 23396734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial.
    Rodriguez-Torres M; Slim J; Bhatti L; Sterling R; Sulkowski M; Hassanein T; Serrão R; Sola R; Bertasso A; Passe And S; Stancic S
    HIV Clin Trials; 2012; 13(3):142-52. PubMed ID: 22592094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.
    Poizot-Martin I; Bellissant E; Garraffo R; Colson P; Piroth L; Solas C; Renault A; Bourlière M; Halfon P; Ghosn J; Alric L; Naqvi A; Carrieri P; Molina JM;
    HIV Clin Trials; 2016 Mar; 17(2):63-71. PubMed ID: 27077673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
    Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
    J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals.
    Hopkins S; Lambourne J; Farrell G; McCullagh L; Hennessy M; Clarke S; Mulcahy F; Bergin C
    HIV Med; 2006 May; 7(4):248-54. PubMed ID: 16630037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
    Pineda JA; Mira JA; Gil Ide L; Valera-Bestard B; Rivero A; Merino D; Girón-González JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Carrillo-Gómez R; López-Cortés LF; Gómez-Mateos J
    J Antimicrob Chemother; 2007 Dec; 60(6):1347-54. PubMed ID: 17938129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.
    Murata M; Furusyo N; Ogawa E; Mitsumoto F; Hiramine S; Ikezaki H; Takayama K; Shimizu M; Toyoda K; Kainuma M; Hayashi J
    J Infect Chemother; 2014 May; 20(5):320-4. PubMed ID: 24477330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus.
    Yu JW; Sun LJ; Zhao YH; Kang P; Gao J; Li SC
    Liver Int; 2009 Nov; 29(10):1485-93. PubMed ID: 19602134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HCV viral decline at week 2 of Peg-IFN-alpha-2a/RBV therapy as a predictive tool for tailoring treatment in HIV/HCV genotype 1 co-infected patients.
    Rivero-Juarez A; López-Cortés LF; Camacho A; Torres-Cornejo A; Gordon A; Ruiz-Valderas R; Torre-Cisneros J; Pineda JA; Viciana P; Rivero A
    PLoS One; 2014; 9(6):e99468. PubMed ID: 24945348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
    Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA
    PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dose-response relationship of peginterferon alfa-2a and ribavirin in the treatment of patients coinfected with HIV-HCV.
    Opravil M; Rodriguez-Torres M; Rockstroh J; Snoeck E; Chung RT; Tietz A; Torriani FJ
    HIV Clin Trials; 2012; 13(1):33-45. PubMed ID: 22306586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis.
    Shire NJ; Welge JA; Sherman KE
    J Viral Hepat; 2007 Apr; 14(4):239-48. PubMed ID: 17381715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real life experience in treatment of HIV-1/HCV-coinfected patients with pegylated interferon alpha and ribavirin: predictors of SVR.
    Bruno G; Fasano M; Saracino A; Volpe A; Bartolomeo N; Ladisa N; Maggi P; Monno L; Angarano G
    New Microbiol; 2015 Jan; 38(1):21-7. PubMed ID: 25742144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.
    Pontali E; Angeli E; Cattelan AM; Maida I; Nasta P; Verucchi G; Caputo A; Iannacone C; Puoti M
    Antivir Ther; 2015; 20(1):39-48. PubMed ID: 24831457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients.
    Tural C; Galeras JA; Planas R; Coll S; Sirera G; Giménez D; Salas A; Rey-Joly C; Cirera I; Márquez C; Tor J; Videla S; García-Retortillo M; Clotet B; Solà R
    Antivir Ther; 2008; 13(8):1047-55. PubMed ID: 19195330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin.
    Monje-Agudo P; Castro-Iglesias A; Rivero-Juárez A; Martínez-Marcos F; Ortega-González E; Real LM; Pernas B; Merchante N; Cid P; Macías J; Merino MD; Rivero A; Mena A; Neukam K; Pineda JA;
    Eur J Clin Microbiol Infect Dis; 2015 Oct; 34(10):1929-36. PubMed ID: 26155784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
    Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM;
    Clin Infect Dis; 2014 Dec; 59(12):1768-76. PubMed ID: 25139963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.